{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:50Z","timestamp":1791559430366,"version":"4.3.4"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Small cell lung cancer (SCLC) is highly aggressive, and durable disease control after multiple treatment lines is uncommon. Anti-angiogenic therapy combined with PD-1 blockade may provide complementary antitumor effects through vascular and immune microenvironment remodeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a 64-year-old never-smoking woman diagnosed with limited-stage SCLC in September 2017. She achieved a partial response after concurrent chemoradiotherapy but developed recurrence in November 2018 and subsequently progressed after irinotecan-based and pemetrexed-based chemotherapy. Anlotinib was initiated in August 2019 and achieved radiologic tumor regression. In May 2020, biopsy of a right submandibular lymph node confirmed extrathoracic metastatic SCLC. Sintilimab was added to ongoing anlotinib in June 2020, and a partial response was achieved after three cycles. Grade 2 immune-related hypothyroidism developed during combination therapy, and sintilimab was discontinued. Anlotinib monotherapy was subsequently continued as maintenance treatment. At the latest follow-up in July 2026, the patient remained alive with stable disease, with an overall survival of 106 months from initial diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case highlights exceptionally durable disease control in multiply relapsed SCLC following sequential anlotinib and short-course sintilimab. The sustained activity of anlotinib, reactivation of antitumor immunity by PD-1 blockade, and potential vascular\u2013immune interaction may have jointly contributed to the prolonged outcome. However, because anlotinib had demonstrated activity before immunotherapy and was continued after sintilimab discontinuation, the relative contribution of each treatment cannot be determined. Further prospective studies with biomarker analyses are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1902026","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:44:52Z","timestamp":1788929092000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Exceptional 106-month survival in multiply relapsed small cell lung cancer after sequential anlotinib and short-course sintilimab: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Ruzhu","family":"Wang","sequence":"first","affiliation":[{"name":"College of Health-Preservation and Wellness, Dalian Medical University","place":["Dalian, China"]},{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Health-Preservation and Wellness, Dalian Medical University","place":["Dalian, China"]},{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Health-Preservation and Wellness, Dalian Medical University","place":["Dalian, China"]},{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.87","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01356-3","article-title":"Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled phase 2 study","volume":"125","author":"Cheng","year":"2021","journal-title":"Br J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1291530","article-title":"Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy","volume":"14","author":"Qian","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5524685","article-title":"Real-world survival in patients with metastatic melanoma after discontinuation of anti-PD-1 immunotherapy for objective response or adverse effects: a retrospective study","volume":"2021","author":"Valentin","year":"2021","journal-title":"J Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.ccr-21-2241","article-title":"Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma","volume":"28","author":"Su","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102543","article-title":"Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial","volume":"70","author":"Ma","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1902026\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:45:04Z","timestamp":1788929104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1902026\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":12,"alternative-id":["10.3389\/fonc.2026.1902026"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1902026","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1902026"}}